Repositioning Candidate Details
| Candidate ID: | R0440 |
| Source ID: | DB06199 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Atrasentan |
| Synonyms: | |
| Molecular Formula: | C29H38N2O6 |
| SMILES: | CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1=CC=C(OC)C=C1)C(O)=O)C1=CC2=C(OCO2)C=C1 |
| Structure: |
|
| DrugBank Description: | Atrasentan is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists. It is a novel, selective endothelin A receptor antagonist (SERA). |
| CAS Number: | 173937-91-2 |
| Molecular Weight: | 510.6218 |
| DrugBank Indication: | Investigated for use/treatment in prostate cancer and cancer/tumors (unspecified). |
| DrugBank Pharmacology: | |
| DrugBank MoA: | |
| Targets: | Endothelin-1 receptor |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|